Genovis signs license agreement with Life Technologies Corporation
Genovis has entered into a license agreement with Life Technologies a wholly owned subsidiary of Thermo Fisher Scientific and is launching a unique new technology for labeling antibodies. The first product, GlyCLICK™, will be launched in the autumn.Labeling of antibodies includes several elements in the chain from development, preclinical, diagnostic and therapeutic applications in the pharmaceutical industry. By combining Genovis’ unique enzymes with SiteClick™ technology from Life Technologies antibodies will be labeled precisely and completely at the same site each time, regardless of